

Chrystal M Paulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2770253/publications.pdf>

Version: 2024-02-01

85
papers

9,065
citations

87888

38
h-index

64796

79
g-index

92
all docs

92
docs citations

92
times ranked

14339
citing authors

#	ARTICLE	IF	CITATIONS
1	B cells imprint adoptively transferred CD8 ⁺ T cells with enhanced tumor immunity. , 2022, 10, e003078.		7
2	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	4
3	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2022, 28, 4336-4345.	7.0	3
4	Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma. Journal of Geriatric Oncology, 2021, 12, 394-401.	1.0	7
5	Modeling <i>ex vivo</i> tumor-infiltrating lymphocyte expansion from established solid malignancies. OncolImmunology, 2021, 10, 1959101.	4.6	3
6	Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Medicine, 2021, 10, 1805-1814.	2.8	17
7	Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 645242.	4.8	69
8	Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans. Frontiers in Oncology, 2021, 11, 659036.	2.8	2
9	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2ndâ€“3rd,) Tj ETQq1 1 0.784314 rgBT /	4.4	1
10	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-Î³ (RORÎ³) Agonist for Use in Treating Cancer. Journal of Medicinal Chemistry, 2021, 64, 13410-13428.	6.4	11
11	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100411.	6.5	18
12	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100426.	6.5	28
13	Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncology, The, 2021, 22, 1777-1786.	10.7	75
14	Platelet and hemoglobin count at diagnosis are associated with survival in African American and Caucasian patients with colorectal cancer. Cancer Epidemiology, 2020, 67, 101746.	1.9	13
15	The Great Debate at â€œImmunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
16	Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 ⁺ T cells. European Journal of Immunology, 2020, 50, 1386-1399.	2.9	38
17	RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. Science Advances, 2020, 6, eaaz3865.	10.3	32
18	IL6 Fuels Durable Memory for Th17 Cellâ€“Mediated Responses to Tumors. Cancer Research, 2020, 80, 3920-3932.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 229.	2.6	30
20	Identification of human CD4 ⁺ T cell populations with distinct antitumor activity. <i>Science Advances</i> , 2020, 6, .	10.3	27
21	Racial disparity in survival of patients diagnosed with early-onset colorectal cancer. <i>Colorectal Cancer</i> , 2020, 9, .	0.8	2
22	Molecular properties of gp100-reactive T cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 68-78.	3.3	9
23	Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. <i>Cell Reports</i> , 2019, 28, 1879-1893.e7.	6.4	71
24	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. <i>Oncology Reviews</i> , 2019, 13, 430.	1.8	9
25	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. <i>Trends in Cancer</i> , 2019, 5, 208-232.	7.4	54
26	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. <i>Frontiers in Immunology</i> , 2019, 10, 263.	4.8	69
27	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2574-2574.	1.6	22
28	Immune signatures associated with response to neoadjuvant PD-1 blockade in oral cavity cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6055-6055.	1.6	5
29	Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. <i>Cancer Research</i> , 2018, 78, 3067-3074.	0.9	6
30	N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 691-702.	4.2	30
31	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	1.2	83
32	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. <i>Cancer</i> , 2018, 124, 1650-1659.	4.1	32
33	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. <i>Cellular and Molecular Immunology</i> , 2018, 15, 458-469.	10.5	331
34	Clinical and basic immunodermatology, 2nd ed. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, e133.	1.2	0
35	CD38-NAD ⁺ Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. <i>Cell Metabolism</i> , 2018, 27, 85-100.e8.	16.2	197
36	<i>In Vitro</i> Priming of Adoptively Transferred T Cells with a ROR ¹ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> . <i>Cancer Research</i> , 2018, 78, 3888-3898.	0.9	30

#	ARTICLE	IF	CITATIONS
37	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. <i>Frontiers in Immunology</i> , 2018, 9, 1740.	4.8	155
38	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82.	17.0	105
39	Resident memory T cells in the skin mediate durable immunity to melanoma. <i>Science Immunology</i> , 2017, 2, .	11.9	209
40	Platelets subvert T cell immunity against cancer via GARP-TGF β 2 axis. <i>Science Immunology</i> , 2017, 2, .	11.9	237
41	Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. <i>Transplantation</i> , 2017, 101, e75-e85.	1.0	15
42	Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 737-751.	4.2	7
43	Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. <i>Molecular Therapy</i> , 2017, 25, 1995-1996.	8.2	1
44	Human CD26 ^{high} T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. <i>Nature Communications</i> , 2017, 8, 1961.	12.8	67
45	Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. <i>Scientific Reports</i> , 2017, 7, 15552.	3.3	24
46	Modulation of Endoplasmic Reticulum Stress Controls CD4 ⁺ T-cell Activation and Antitumor Function. <i>Cancer Immunology Research</i> , 2017, 5, 666-675.	3.4	35
47	PI3K γ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8 ⁺ T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1221.	4.8	56
48	β 2-catenin and PI3K γ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. <i>JCI Insight</i> , 2017, 2, .	5.0	35
49	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. <i>JCI Insight</i> , 2017, 2, e90772.	5.0	54
50	The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. <i>Journal of Immunology Research and Therapy</i> , 2017, 2, 68-79.	1.0	20
51	Harnessing the IL-7/IL-7R α axis to improve tumor immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1122865.	4.6	3
52	Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis. <i>Inflammation</i> , 2016, 39, 1345-1353.	3.8	7
53	Lack of <i>p53</i> Augments Antitumor Functions in Cytolytic T Cells. <i>Cancer Research</i> , 2016, 76, 5229-5240.	0.9	34
54	Synthetic ROR γ agonists regulate multiple pathways to enhance antitumor immunity. <i>Oncolimmunology</i> , 2016, 5, e1254854.	4.6	68

#	ARTICLE	IF	CITATIONS
55	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning. , 2016, 4, 6.		23
56	Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunology, Immunotherapy, 2016, 65, 247-259.	4.2	35
57	A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, e14579-e14579.	1.6	0
58	Harnessing the Microbiome to Enhance Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	54
59	The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue. Journal of Immunology, 2015, 194, 1737-1747.	0.8	34
60	Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells. Cancer Immunology Research, 2015, 3, 356-367.	3.4	247
61	Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells. Cancer Immunology, Immunotherapy, 2015, 64, 539-549.	4.2	33
62	Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clinical Cancer Research, 2015, 21, 2546-2557.	7.0	25
63	IL-2R β mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Science Translational Medicine, 2015, 7, 311ra170.	12.4	49
64	Novel immunotherapies for hematologic malignancies. Immunological Reviews, 2015, 263, 90-105.	6.0	44
65	Th17 Cells in Cancer: The Ultimate Identity Crisis. Frontiers in Immunology, 2014, 5, 276.	4.8	257
66	Folate Receptor- β in Activated Macrophages: Ligand Binding and Receptor Recycling Kinetics. Molecular Pharmaceutics, 2014, 11, 3609-3616.	4.6	40
67	Reducing CD73 Expression by IL1 β -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. Cancer Research, 2014, 74, 6048-6059.	0.9	49
68	Ex Vivo Interleukin-12-Priming During CD8+ T Cell Activation Dramatically Improves Adoptive T Cell Transfer Antitumor Efficacy in a Lymphodepleted Host. Journal of the American College of Surgeons, 2012, 214, 700-707.	0.5	30
69	A human memory T cell subset with stem cell-like properties. Nature Medicine, 2011, 17, 1290-1297.	30.7	1,547
70	Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. Cancer Research, 2010, 70, 9053-9061.	0.9	388
71	The Inducible Costimulator (ICOS) Is Critical for the Development of Human T _H 17 Cells. Science Translational Medicine, 2010, 2, 55ra78.	12.4	221
72	Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. Journal of Clinical Investigation, 2010, 120, 76-80.	8.2	65

#	ARTICLE	IF	CITATIONS
73	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. <i>Nature Medicine</i> , 2009, 15, 808-813.	30.7	839
74	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. <i>Immunologic Research</i> , 2008, 42, 182-196.	2.9	47
75	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. <i>Blood</i> , 2008, 111, 5326-5333.	1.4	380
76	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8061-8066.	7.1	114
77	Tumor-specific Th17-polarized cells eradicate large established melanoma. <i>Blood</i> , 2008, 112, 362-373.	1.4	719
78	Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.	7.0	114
79	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. <i>Journal of Clinical Investigation</i> , 2007, 117, 2197-2204.	8.2	456
80	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2007, 117, 492-501.	8.2	181
81	Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. <i>Journal of Immunology</i> , 2006, 176, 5255-5266.	0.8	109
82	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. <i>Blood</i> , 2006, 108, 5210-5210.	1.4	0
83	O,O-Diethyl phthalimidophosphonothioate (Ditalimphos). <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2005, 61, o2352-o2353.	0.2	1
84	Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery. <i>Molecular Pharmacology</i> , 2004, 66, 1406-1414.	2.3	211
85	Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1205-1217.	13.7	258